DBV Technologies (NASDAQ:DBVT) Stock Rating Upgraded by The Goldman Sachs Group

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by equities research analysts at The Goldman Sachs Group to a "sell" rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm presently has a $7.25 price target on the stock. The Goldman Sachs Group's price target would indicate a potential downside of 8.86% from the company's previous close.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. HC Wainwright boosted their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. Finally, JMP Securities raised their price target on shares of DBV Technologies from $15.00 to $21.00 and gave the stock a "market outperform" rating in a report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $14.75.

DBV Technologies Stock Down 4.7%

DBV Technologies stock traded down $0.40 during trading hours on Thursday, reaching $7.96. 20,495 shares of the company's stock were exchanged, compared to its average volume of 190,806. The firm's 50 day simple moving average is $8.44 and its 200 day simple moving average is $5.52. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78. The firm has a market capitalization of $217.89 million, a PE ratio of -1.79 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The business had revenue of $0.51 million for the quarter. Analysts anticipate that DBV Technologies will post -7.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.